Harbour BioMed Announces First Patient Dosed in Phase I Study of First-in-Class Anti-B7H7 (HHLA2) Antibody HBM1020 ...Middle East

HBM1020 is a first-in-class therapeutic monoclonal antibody against B7H7/HHLA2 entering clinical development globally. HBM1020 was generated from Harbour Mice® H2L2 transgenic mice platform. HBM1020 has great potential to address huge unmet medical needs in patients with advanced...

Hence then, the article about harbour biomed announces first patient dosed in phase i study of first in class anti b7h7 hhla2 antibody hbm1020 was published today ( Monday 05/06/2023 - 04:08 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Harbour BioMed Announces First Patient Dosed in Phase I Study of First-in-Class Anti-B7H7 (HHLA2) Antibody HBM1020 )

Also on site :

• William Shatner, 95, Walked Onstage With a Band Nobody Expected Him to Front; the ‘Star Trek’ Legend Covered Ozzy Osbourne and Metallica in Chicago
• Sean Hogan’s ‘The Dark Gets In’ Boarded for Worldwide Sales by Blue Finch Films Ahead of Beyond Fest Bow (EXCLUSIVE)
• Envision Energy Powers Morocco's First Large-Scale Battery Storage System at OCP's Benguerir Mining Site